Cargando…

Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy

OBJECTIVE: To investigate pharmacokinetic changes in newer antiepileptic drugs (AEDs) and assess seizure frequencies and risk factors of increased seizures during pregnancy in women with epilepsy (WWE). METHODS: A total of 56 pregnancies in 53 WWE who received newer antiepileptic drugs (AEDs) were e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xiaotong, Liu, Yan, Guo, Yang, Zhao, Limei, Li, Guofei, Tan, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981429/
https://www.ncbi.nlm.nih.gov/pubmed/35037389
http://dx.doi.org/10.1111/cns.13796
_version_ 1784681601998782464
author Yin, Xiaotong
Liu, Yan
Guo, Yang
Zhao, Limei
Li, Guofei
Tan, Xiaoping
author_facet Yin, Xiaotong
Liu, Yan
Guo, Yang
Zhao, Limei
Li, Guofei
Tan, Xiaoping
author_sort Yin, Xiaotong
collection PubMed
description OBJECTIVE: To investigate pharmacokinetic changes in newer antiepileptic drugs (AEDs) and assess seizure frequencies and risk factors of increased seizures during pregnancy in women with epilepsy (WWE). METHODS: A total of 56 pregnancies in 53 WWE who received newer antiepileptic drugs (AEDs) were enrolled. Data on seizure activity and types, daily dose, and AEDs blood levels were derived from routine clinical follow‐up. Changes in AEDs clearance were compared between each trimester and nonpregnant baseline. The ratio of AED levels of each trimester to their targets (nonpregnant baseline) concentrations (RTC) was compared between patients with and without an increased seizure. A binary logistic regression was used to investigate the risk factors contributing to seizure worsening during pregnancy. RESULTS: Increased clearances of LTG, LEV, and OXC were observed in all trimesters versus nonpregnant baseline. The peak changes in the clearance of LTG (3.42‐fold baseline clearance) (p < 0.001) and LEV (2.78‐fold) (p < 0.001) occurred in the second trimester during pregnancy, followed by oxcarbazepine (2.11‐fold) in the third trimester (p < 0.03). Plasma concentrations of LTG and LEV during pregnancy were significantly decreased compared to baseline levels, except for OXC. However, no significant differences in RTC values were observed between patients with and without seizure worsening. Some risk factors as seizures for the prior nine months could significantly affect seizure frequency during pregnancy. CONCLUSION: We found substantial changes in the pharmacokinetics of multiple newer AEDs in WWE, reinforcing the need for therapeutic drug monitoring (TDM) during pregnancy. We would encourage at least one monitoring every trimester and probably more frequently for women with poorly seizure control before pregnancy, and AEDs dose adjustment should keep up with clearance changes. In addition, a well‐controlled seizure nine months before pregnancy could lower the risks of seizure during pregnancy, highlighting the importance of pre‐pregnancy counseling and seizure management before pregnancy.
format Online
Article
Text
id pubmed-8981429
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89814292022-04-11 Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy Yin, Xiaotong Liu, Yan Guo, Yang Zhao, Limei Li, Guofei Tan, Xiaoping CNS Neurosci Ther Original Articles OBJECTIVE: To investigate pharmacokinetic changes in newer antiepileptic drugs (AEDs) and assess seizure frequencies and risk factors of increased seizures during pregnancy in women with epilepsy (WWE). METHODS: A total of 56 pregnancies in 53 WWE who received newer antiepileptic drugs (AEDs) were enrolled. Data on seizure activity and types, daily dose, and AEDs blood levels were derived from routine clinical follow‐up. Changes in AEDs clearance were compared between each trimester and nonpregnant baseline. The ratio of AED levels of each trimester to their targets (nonpregnant baseline) concentrations (RTC) was compared between patients with and without an increased seizure. A binary logistic regression was used to investigate the risk factors contributing to seizure worsening during pregnancy. RESULTS: Increased clearances of LTG, LEV, and OXC were observed in all trimesters versus nonpregnant baseline. The peak changes in the clearance of LTG (3.42‐fold baseline clearance) (p < 0.001) and LEV (2.78‐fold) (p < 0.001) occurred in the second trimester during pregnancy, followed by oxcarbazepine (2.11‐fold) in the third trimester (p < 0.03). Plasma concentrations of LTG and LEV during pregnancy were significantly decreased compared to baseline levels, except for OXC. However, no significant differences in RTC values were observed between patients with and without seizure worsening. Some risk factors as seizures for the prior nine months could significantly affect seizure frequency during pregnancy. CONCLUSION: We found substantial changes in the pharmacokinetics of multiple newer AEDs in WWE, reinforcing the need for therapeutic drug monitoring (TDM) during pregnancy. We would encourage at least one monitoring every trimester and probably more frequently for women with poorly seizure control before pregnancy, and AEDs dose adjustment should keep up with clearance changes. In addition, a well‐controlled seizure nine months before pregnancy could lower the risks of seizure during pregnancy, highlighting the importance of pre‐pregnancy counseling and seizure management before pregnancy. John Wiley and Sons Inc. 2022-01-17 /pmc/articles/PMC8981429/ /pubmed/35037389 http://dx.doi.org/10.1111/cns.13796 Text en © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Yin, Xiaotong
Liu, Yan
Guo, Yang
Zhao, Limei
Li, Guofei
Tan, Xiaoping
Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
title Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
title_full Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
title_fullStr Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
title_full_unstemmed Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
title_short Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
title_sort pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981429/
https://www.ncbi.nlm.nih.gov/pubmed/35037389
http://dx.doi.org/10.1111/cns.13796
work_keys_str_mv AT yinxiaotong pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy
AT liuyan pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy
AT guoyang pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy
AT zhaolimei pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy
AT liguofei pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy
AT tanxiaoping pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy